Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks Jivi's performance in hemophilia a patients

NCT ID NCT03932201

Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study looks at how the drug Jivi (damoctocog alfa pegol) works for people with hemophilia A in real-world settings, not just in controlled trials. Researchers are tracking bleeding episodes, side effects, and how satisfied patients and doctors are with the treatment. About 371 people who have used Jivi before are taking part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

371 people

The number who actually took part.

Started

Oct 2019

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Previously treated patients with hemophilia A receiving damoctocog alfa pegol with any kind of treatment modality (on-demand, prop hylaxis, or intermittent prophylaxis).

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of hemophilia A. * Patients previously treated for Hemophilia A. * Patients without previous history of inhibitors or patients with previous history of inhibitors on standard prophylaxis therapy for at least 1 year prior to study entry. * No current evidence of FVIII inhibitor or clinical suspicion of FVIII inhibitor. * Initiation of or currently on damoctocog alfa pegol with any kind of treatment modality (on-demand, prophylaxis, or intermittent prophylaxis). * Signed informed consent/assent. Exclusion Criteria: * Concurrent participation in an investigational program with interventions outside of routine clinical practice. * Diagnosis of any other bleeding/coagulation disorder other than hemophilia A. * Contra-indications according to the local marketing authorization. * Patient on immune tolerance induction (ITI) treatment at the time of enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemophilia A are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemophilia A

Contacts and locations

Locations

  • Banner MD Anderson Cancer Center

    Phoenix, Arizona, 85012, United States

  • East Carolina University - Brody School of Medicine

    Greenville, North Carolina, 27834, United States

  • Georgetown University

    Washington D.C., District of Columbia, 20007, United States

  • Many locations

    Multiple Locations, Belgium

  • Many locations

    Multiple Locations, Brazil

  • Many locations

    Multiple Locations, Canada

  • Many locations

    Multiple Locations, Colombia

  • Many locations

    Multiple Locations, Denmark

  • Many locations

    Multiple Locations, Germany

  • Many locations

    Multiple Locations, Greece

  • Many locations

    Multiple Locations, Italy

  • Many locations

    Multiple Locations, Japan

  • Many locations

    Multiple Locations, Kuwait

  • Many locations

    Multiple Locations, Netherlands

  • Many locations

    Multiple Locations, Norway

  • Many locations

    Multiple Locations, Saudi Arabia

  • Many locations

    Multiple Locations, Slovenia

  • Many locations

    Multiple Locations, Spain

  • Many locations

    Multiple Locations, Sweden

  • Many locations

    Multiple Locations, Switzerland

  • Many locations

    Multiple Locations, Taiwan

  • Many locations

    Multiple Locations, United Arab Emirates

  • Orthopaedic Hospital DBA Orthopaedic Institute for Children

    Los Angeles, California, 90007, United States

  • Regents of University of Minnesota

    Minneapolis, Minnesota, 55454, United States

  • South Alabama Medical Science Foundation

    Mobile, Alabama, 36688, United States

  • The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders

    Orange, California, 92868, United States

  • Tulane University

    New Orleans, Louisiana, 70112, United States

  • University California Davis

    Davis, California, 95616, United States

  • University of Colorado Hemophilia and Thrombosis Center

    Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.